CYTO (altamiratherapeutics.com) Future Price to Earnings
Altamira Therapeutics (CYTO) owns an active substance delivery platform, enabling the company to scale its business through royalties. The company's forward P/E ratio confirms this potential, with 0.00 indicating the level of this metric. The development of nasal sprays for RNA therapy expands patient reach for ENT pathologies, while an organic technology licensing strategy for big pharma behemoths establishes a foundation for long-term growth.
Summary analytical data breakdowns for Auris Medical (CYTO)
- current price and projected stock value:
- business market valuation indicators:
- balance sheet equity data:
- debt level and financial liquidity data:
Total Debt to Capital Altamira Therapeutics|CYTO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Altamira Therapeutics|CYTO - Aggregate Debt Obligations|Debts to Book Capitalization Altamira Therapeutics Ltd|CYTO - Company Long-Term Debts|Company Short-Term Debt Altamira Therapeutics|Quick Liquidity Indicator altamiratherapeutics.com
- financial results and valuation multiples details:
CYTO - Profit After Payment of Taxes|Projected Future Earnings Altamira Therapeutics|CYTO - P/E Multiple|Future Price to Earnings Altamira Therapeutics|CYTO - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Altamira Therapeutics Ltd|CYTO - Operating income before deduction of amortization|Earnings per share for the last twelve months Altamira Therapeutics|CYTO - Earnings per share for the trailing year|Quarterly EPS earnings growth altamiratherapeutics.com|CYTO - Earnings growth in current year|Expected earnings per share growth for next year Altamira Therapeutics
- company sales and revenue statistics:
Fundamental valuation:Altamira Therapeutics Ltd.
For the intranasal RNA drug venture ecosystem of Altamira Therapeutics (CYTO), the company's forward P/E ratio serves as a gauge of market optimism regarding the future monetization of clinical trials. By dividing market capitalization by expected annual earnings, this chart assesses investors' willingness to pay a premium for the potential success of the sprays, while high volatility in the metric signals risks associated with stringent regulatory control over system toxicity.
Analysis of competing companies
Projected Price to Earnings HLN (Haleon)|KVUE (Kenvue Inc) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma Corp VRNA|Jyong Bio (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|amneal.com - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech S.A. - Future Price to Earnings Multiple|LQDA (Liquidia Technologies) - Forward P/E Multiple|Projected Price to Earnings Ratio Galapagos Corp GLPG|Future Price to Earnings ANI Pharmaceuticals (ANIP)|MNKD (mannkindcorp.com) - Future Price to Earnings Multiple|Forward P/E Multiple AMPH (Amphastar Pharmaceuticals, Inc.)|Forward P/E Multiple Pacira Pharmaceuticals PCRX|SPRY - Future Price to Earnings|TBPH: Future Price to Earnings|AQST (Aquestive Therapeutics) - Projected Price to Earnings|SCPH: Market Cap to Future Earnings Ratio|TECX (Tectonic Therapeutic Inc.) - Forward P/E Multiple|Forward P/E Multiple Tonix Pharma|Future Price to Earnings China SXT Pharmaceuticals (SXTC)|Projected Price to Earnings eupraxiapharma.com EPRX|Forward P/E Multiple BHST (BioHarvest Sciences)|Market Cap to Projected Earnings invizyne.com (EXOZ)|ORMP - Future Price to Earnings|Future Price to Earnings Multiple ENTX (Entera Bio Ltd.)|HYFT: Forward P/E Multiple|ABVC BioPharma, Inc (ABVC) - Forward P/E Multiple|Projected Price to Earnings CPIX|QNTM: Future Price to Earnings Multiple|Projected Price to Earnings FGEN (FibroGen)|Market Cap to Future Earnings Ratio TELO|Forward P/E Multiple RANI (Rani Therapeutics Holdings, Inc.)|Future Price to Earnings Multiple SNYR|Rallybio Corp. - Forward P/E Multiple|Projected Price to Earnings Ratio Lexaria Bioscience|Pulmatrix (PULM) - Future Price to Earnings|Pheton Holdings - Future Price to Earnings Multiple|APM (Aptorum Group Ltd) - Forward P/E Multiple|Forward P/E Multiple Lyra Therapeutics Inc|Future Price to Earnings Impact BioMedical Inc (IBO)|TNFA: Price to Expected Earnings Ratio|Forward P/E Multiple YCBD (cbdMD)|PainReform Ltd (PRFX) - Projected Price to Earnings Ratio|LIPO: Projected Price to Earnings|OPTN - Forward P/E Multiple|PIRS (Pieris Pharmaceuticals) - Projected Price to Earnings|PROC: Market Cap to Future Earnings Ratio|PTPI (Petros Pharmaceuticals, Inc.) - Forward P/E Multiple|Qilian International Holding Group (QLI) - Market Cap to Projected Earnings|Forward P/E Multiple SLRN|Projected Price to Earnings TFF Pharmaceuticals, Inc TFFP
